SlideShare uma empresa Scribd logo
1 de 36
Baixar para ler offline
Dr. RAGHU PRASADA M S
MBBS,MD
ASSISTANT PROFESSOR
DEPT. OF PHARMACOLOGY
SSIMS & RC.
1
 Central Nervous System (CNS) - Brain and spinal
cord
 Peripheral Nervous System (PNS) - Located
outside the brain & spinal cord Autonomic
Nervous System (ANS) & the somatic
 The PNS receives stimuli from the CNS & initiates
responses to the stimuli after it’s interpreted by the
brain
 Acetylcholine –preganglionic
 Post ganglionicAch
 Exception-post ganglionic sympathetic fibres to
apocrine glands
 Cholinergic fibres
 All somatic motar neurons
 All preganglionic fibres
 Post ganglionic parasympathetic fibres
 75% of all parasympathetic nerve fibers are in the
vagus nerves
 These nerves supply the thoracic and abdominal
organs, which innervate the heart, lungs, esophagus,
stomach, small intestine, proximal half of the colon,
liver , gallbladder, pancreas and upper portions of
the ureters
Natural alkaloids: Atropine (spasmolytic, mydriatic),
Hyoscine (Scopolamine), (antiemetic)
2. Semisynthetic derivatives
Mydriatics: Homatropine, Tropicamide
GI spasmolytics: Hyoscine butyl bromide
3. Synthetic compounds
GI spasmolytics: Oxyphenonium
Antiulcer drugs: Pirenzepine (M1-blockers)
Antiasthmatics: Ipratropium and Tiotropium
Urinary system: Flavoxate, Oxybutynyne, Trospium
Antiparkinsonian (central M-cholinolytics):
Benztropine, Biperiden, Trihexyphenidyl
 Antimuscarinic agents:
These agents block muscarinic receptors and
inhibit muscarinic functions, they are useful in
different clinical situations, they have no actions on
skeletal neuromuscular junctions or autonomic
ganglia because they do not block nicotinic
receptors.
50
100
150
200
A B C D1 min
ATROPINE BLOCKS
M-EFFECTS OF ACH
Bloodpressure[mmHg]
ACh
2 mcg i.v.
ACh
50 mcg
ACh
50 mcg
ACh
5 mg
M-
effect
M-
effect
N-
effect
Atropine
2 mg i.v.
ACh
A belladonna alkaloid has a
high affinity for muscarinic
receptors, it is a competitive
inhibitor of muscarinic receptors
preventing ACH from
binding to that site.
Atropine
 CNS. Atropine has an overall stimulant action. Its
stimulant effects are not appreciable at low doses which
produce peripheral effects because of restricted entry
into the brain. Hyoscine produces central depressant
effects even at low doses.
• Medullar centers - vagal, respiratory, and vasоmotor.
• By blocking the relative cholinergic overactivity in
 basal ganglia, it suppresses tremor and rigidity
 in parkinsonism.
• High doses cause cortical excitation, restlessness,
disorientation, hallucinations, and delirium
 followed by respiratory depression and coma.
Low dose-M2 receptor on cholinergic N auto-
inhibitary cholinergic action bradycardia
Moderate dose- M2 receptor on post junctional SAN,
AVN blkescape the heart from
inhibitiontachycardia+Unopposed adrenegic
action chronotropic, dronotropic
Toxic dose-M3 receptor-endothelium blockade NO
release is blockedsmooth muscle donot
relaxprevention of cholinergic mediated dialation
Autonomic control of pupil (A) and site of
action of mydriatics (B) and miotics (C)
Topical instillation of atropine (0.1%)
causes mydriasis, abolition of light reflex,
and cycloplegia, lasting 7–10 days.
This results in photophobia and blurring
of near vision.
The intraocular tension rises, specially in
narrow angle glaucoma
All visceral smooth muscles with parasympathetic
innervation are relaxed (M3-blokade).
Tone and amplitude of GIT are reduced.
Spasm may be reduced, constipation may occur.
Peristalsis is only incompletely suppressed because it is
primarily regulated by local reflexes and other
neurotransmitters (serotonin, encephalin, etc.).
Atropine causes bronchodilation and reduced airway
resistance, especially in asthma patients.
Inflammatory mediators (histamine, PGs, and kinins)
increase vagal activity in addition to their direct action
on bronchial muscle and glands. Atropine attenuates
their action by antagonizing the reflex vagal component.
It has a relaxant action on the ureter and urinary
bladder. Urinary retention can occur in older men with
prostatic hyperplasia.
Glands. Atropine decreases sweat, salivary, tracheo-
bronchial, and lacrimal secretion (M3-blockade). Skin
and eyes become dry, talking, and swallowing my be
very difficult.
Atropine decreases less the secretion of acid and pep-
sin and more of the mucus in the stomach.
Body temperature. Rise in body temperature occurs at
higher doses, and is due to both inhibition of sweating
as well as stimulation of the temperature regulating
centre in the hypothalamus. Children are highly
susceptible.
Local anaesthetic action. Atropine has a mild
anaesthetic action on the cornea.
The sensitivity of different organs and tissues
to atropine varies and can be graded as
Saliva, sweat, bronchial secretion > eye >
bronchial muscles > heart > intestinal and
bladder smooth muscles > gastric glands
and gastric smooth muscles
Atropine and hyoscine are rapidly absorbed from
GIT. Applied to the eyes they penetrate the cornea.
Passage across BBB is somewhat restricted.
50% of atropine is metabolized in the liver and
excreted unchanged in urine.
It has t1/2 3–4 h.
Hyoscine is more completely metabolized and has
better BBB penetration.
Some rabbits have a specific atropine
esterase which degrades atropine very rapidly.
 Scopalamine (hyoscine): A belladdona alkaloid
produce peripheral effects similar to atropine, it has
greater actions on CNS and longer duration of
action.
Most effective in motion sickness, it is effective also
in blocking short term memory, it produce sedation
but at higher doses cause excitement.
 Depresses CNS and causes amnesia, drowsiness,
euphoria, relaxation and sleep.
 Given parenterally, orally and transdermally.
 It is inhalational derivative of atropine useful in
treating asthma and COPD in patients unable to take
adrenergic agonist. Useful in rhinorrhea. Also
excellent bronchodilator.

Agents like homatropine, cyclopentolate, and
tropicamide used mainly in ophthalmology.
 Benztropine-used in drug induced Parkinson’s
disease. Useful for dystonic reactions caused by
antipsychotics.
 Trihexyphenidyl -also used for treating Extra
Pyramidal Symptoms caused by some antipsychotics.
 Flavoxate-relieves dysuria, urgency, frequency and
pain with genito-urinary infections
 Oxybutynin -has direct antispasmodic effects on
smooth muscle and anticholinergic effects.
Decreases frequency of voiding.
 Tolterodine -is competitive, antimuscuranic
anticholinergic that inhibits contraction. More
selective for this area than elsewhere in the body.
- They act on nicotinic receptors of the autonomic
ganglia.
- They have no selectivity toward the parasympathetic
or sympathetic ganglia .
- The effect of these drugs is complex and
unpredictable so rarely used therapeutically,
- Used mainly in experimental pharmacology.
- Increase peristalsis and secretions.
- On large dose of nicotine 
- A)Blood pressure falls because of ganglionic blockade
- B)Activity both in GIT and UB musculature decrease.
Short acting competitive nicotinic ganglionic blocker
that must be given by i.v infusion
It is used for the emergency lowering of the blood
pressure in hypertension caused by pulmonary
edema or dissecting aortic aneurysm, when other
agents cannot be used.
- Drugs that block cholinergic transmission between
motor nerve ending and the nicotinic receptors on
the neuromuscular end plate of the skeletal muscle.
- They are structural analogs of ACH.
 Mydriatic and cycloplegic agent in the eye to permit
measurement of refractive errors. Mydriasis and
cycloplegia for surgery
 RS-In bronchospasm whether related to asthma or
COPD bronchodilating effects
 CVS-Atropine is used to increase heart rate in
symptomatic bradycardias and higher blocks
 GIT-Antispasmodic agent: Relax GIT and bladder.
Helpful in treating irritable colon or colitis
 Useful in gastritis, pylorospasm and ulcerative colitis
as they slow motility
 Antispasmotic effects seen in overactive bladder and
in urinary incontinence
 Antidote for cholinergic agonists: To treat
organophsphorus poisoning (present in insecticides),
and mushroom poisoning.
Antisecretory agent: To block the secretion of upper
and lower respiratory tracts prior to surgery.
 Helps to prevent vagal stimulation and potential
bradycardia
CNS- Parkinson’s Disease-
Useful in those with minimal side effects
Those who cannot take Levodopa
Helpful in decreasing salivation, spasticity and tremors
Absorption of other drugs is slowed because atropine
delays gastric emptying. So dose of levodopa, in
parkinsonism may have to be increased. But the extent of
digoxin and tetracyclines absorption may be increased.
Antacids interfere with the absorption of anticholinergics.
Antihistaminics, tricyclic antidepressants, phenothiazines,
pethidine have anticholinergic property additive side
effects
MAO inhibitors interfere with the metabolism of central
antiparkinsonian drugs (biperiden and others) delirium
may occur.
 BPH
 Myasthenia gravis
 Hyperthyroidism
 Glaucoma
 Tachydysrhythmias
 Dry mouth, difficulty in swallowing and talking;
 Difficulty in micturition
 Dilated pupils, photophobia, blurring of near vision;
palpitation; excitement, psychotic behavior,
 Ataxia, delirium, hallucinations; hypotension, weak
and rapid pulse, cardiovascular collapse with
respiratory depression;
 Convulsion and coma (in very high doses).
 It is very risky in individuals with glaucoma and BPH
Diagnosis: 1 mg neostigmine s.c. fails to induce
typical M-effects.
Treatment: Gastric lavage with tannic acid (KMnO4 is
ineffective in oxidation of atropine). The patient must
be kept in a dark quiet room. Galantamine or physo-
stigmine (1-3 mg s.c./i.v.), diazepam against
convulsion.
THANKYOU
Download slides from
Authorstream/presentations/raghuprasada
Slideshare/presentations/raghuprasada
Youtube/raghuprasada

Mais conteúdo relacionado

Mais procurados (20)

Anticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhritiAnticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhriti
 
Anticholinergic drugs
Anticholinergic drugsAnticholinergic drugs
Anticholinergic drugs
 
Anti cholinergic drugs
Anti cholinergic drugsAnti cholinergic drugs
Anti cholinergic drugs
 
Anticholinergic Drugs
Anticholinergic DrugsAnticholinergic Drugs
Anticholinergic Drugs
 
Cholinergic system and drugs
Cholinergic system and drugsCholinergic system and drugs
Cholinergic system and drugs
 
Anticholinergics
AnticholinergicsAnticholinergics
Anticholinergics
 
Antiadrenergic drugs - drdhriti
Antiadrenergic drugs - drdhritiAntiadrenergic drugs - drdhriti
Antiadrenergic drugs - drdhriti
 
Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017
 
Adrenergic Antagonists
Adrenergic AntagonistsAdrenergic Antagonists
Adrenergic Antagonists
 
Anticholinesterases
AnticholinesterasesAnticholinesterases
Anticholinesterases
 
Local anaesthetics
Local anaestheticsLocal anaesthetics
Local anaesthetics
 
Pharmacology cholinergic agonist
Pharmacology   cholinergic agonistPharmacology   cholinergic agonist
Pharmacology cholinergic agonist
 
4. NSAID
4. NSAID4. NSAID
4. NSAID
 
Parasympathomimetics
ParasympathomimeticsParasympathomimetics
Parasympathomimetics
 
Skeletal muscle relaxant
Skeletal muscle relaxantSkeletal muscle relaxant
Skeletal muscle relaxant
 
OPIOID ANALGESICS
OPIOID ANALGESICSOPIOID ANALGESICS
OPIOID ANALGESICS
 
Antiadrenergic Drugs
Antiadrenergic DrugsAntiadrenergic Drugs
Antiadrenergic Drugs
 
Anticholinergic drugs - pharmacology
Anticholinergic drugs - pharmacologyAnticholinergic drugs - pharmacology
Anticholinergic drugs - pharmacology
 
Parasympatholytics
ParasympatholyticsParasympatholytics
Parasympatholytics
 
Pharmacology of Anticholinergics - drdhriti
Pharmacology of Anticholinergics  - drdhriti Pharmacology of Anticholinergics  - drdhriti
Pharmacology of Anticholinergics - drdhriti
 

Semelhante a Class anticholinergic drugs

Class anticholinergic drugs
Class anticholinergic drugsClass anticholinergic drugs
Class anticholinergic drugsRaghu Prasada
 
Anti cholinergic drugs
Anti cholinergic drugsAnti cholinergic drugs
Anti cholinergic drugsMangeshBansod2
 
Parasympathomimetics and parasympatholytics Pharmacology.
Parasympathomimetics and parasympatholytics Pharmacology. Parasympathomimetics and parasympatholytics Pharmacology.
Parasympathomimetics and parasympatholytics Pharmacology. Javeria Fateh
 
Cholinergic receptor antagonists presentation
Cholinergic  receptor  antagonists presentationCholinergic  receptor  antagonists presentation
Cholinergic receptor antagonists presentationsigei meshack
 
anti dirrhoeal and purgative laxatives.pptx
anti dirrhoeal and purgative laxatives.pptxanti dirrhoeal and purgative laxatives.pptx
anti dirrhoeal and purgative laxatives.pptxSaurabh Gupta
 
Class cholinergic drugs
Class cholinergic drugsClass cholinergic drugs
Class cholinergic drugsRaghu Prasada
 
Anticholinergic drugs by. shuaib
Anticholinergic drugs by. shuaibAnticholinergic drugs by. shuaib
Anticholinergic drugs by. shuaibDr.Shuaib Ahmad
 
CLASS GENERAL ANAESTHESIA
CLASS GENERAL ANAESTHESIACLASS GENERAL ANAESTHESIA
CLASS GENERAL ANAESTHESIARaghu Prasada
 
04 Cholinergic Blockers Upd
04 Cholinergic Blockers Upd04 Cholinergic Blockers Upd
04 Cholinergic Blockers UpdNurse Uragon
 
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]Sujit Karpe
 
cholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxcholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxrupeshdalavi
 
Anti-Cholinergic drugs
Anti-Cholinergic drugsAnti-Cholinergic drugs
Anti-Cholinergic drugsEneutron
 
cholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxcholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxSaurabh Gupta
 
Cholinergic drugs.pptx
Cholinergic drugs.pptxCholinergic drugs.pptx
Cholinergic drugs.pptxKrushalPabari
 
Cns stimulants
Cns stimulantsCns stimulants
Cns stimulantsraj kumar
 

Semelhante a Class anticholinergic drugs (20)

Class anticholinergic drugs
Class anticholinergic drugsClass anticholinergic drugs
Class anticholinergic drugs
 
Anti cholinergic drugs
Anti cholinergic drugsAnti cholinergic drugs
Anti cholinergic drugs
 
Anticholinergics
AnticholinergicsAnticholinergics
Anticholinergics
 
neurological drugs.pptx
neurological drugs.pptxneurological drugs.pptx
neurological drugs.pptx
 
Parasympathomimetics and parasympatholytics Pharmacology.
Parasympathomimetics and parasympatholytics Pharmacology. Parasympathomimetics and parasympatholytics Pharmacology.
Parasympathomimetics and parasympatholytics Pharmacology.
 
Cholinergic receptor antagonists presentation
Cholinergic  receptor  antagonists presentationCholinergic  receptor  antagonists presentation
Cholinergic receptor antagonists presentation
 
Anticholinergics
AnticholinergicsAnticholinergics
Anticholinergics
 
anti dirrhoeal and purgative laxatives.pptx
anti dirrhoeal and purgative laxatives.pptxanti dirrhoeal and purgative laxatives.pptx
anti dirrhoeal and purgative laxatives.pptx
 
Atropine
AtropineAtropine
Atropine
 
Class cholinergic drugs
Class cholinergic drugsClass cholinergic drugs
Class cholinergic drugs
 
Anticholinergic drugs by. shuaib
Anticholinergic drugs by. shuaibAnticholinergic drugs by. shuaib
Anticholinergic drugs by. shuaib
 
CLASS GENERAL ANAESTHESIA
CLASS GENERAL ANAESTHESIACLASS GENERAL ANAESTHESIA
CLASS GENERAL ANAESTHESIA
 
04 Cholinergic Blockers Upd
04 Cholinergic Blockers Upd04 Cholinergic Blockers Upd
04 Cholinergic Blockers Upd
 
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]
drugs that affect the autonomic nervous system.ppt [autosaved] [autosaved]
 
cholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxcholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptx
 
Anti-Cholinergic drugs
Anti-Cholinergic drugsAnti-Cholinergic drugs
Anti-Cholinergic drugs
 
cholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptxcholinergics and anticholinergics.pptx
cholinergics and anticholinergics.pptx
 
Parasympatholytic drugs
Parasympatholytic drugsParasympatholytic drugs
Parasympatholytic drugs
 
Cholinergic drugs.pptx
Cholinergic drugs.pptxCholinergic drugs.pptx
Cholinergic drugs.pptx
 
Cns stimulants
Cns stimulantsCns stimulants
Cns stimulants
 

Mais de Raghu Prasada

Class skeletal muscle relaxants
Class skeletal muscle relaxantsClass skeletal muscle relaxants
Class skeletal muscle relaxantsRaghu Prasada
 
Classs drug metabolism
Classs drug metabolismClasss drug metabolism
Classs drug metabolismRaghu Prasada
 
Class antiadrenergic drugs
Class antiadrenergic drugsClass antiadrenergic drugs
Class antiadrenergic drugsRaghu Prasada
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugsRaghu Prasada
 
Class miscellaneous antibiotics
Class miscellaneous antibioticsClass miscellaneous antibiotics
Class miscellaneous antibioticsRaghu Prasada
 
Class drug absorption
Class drug absorptionClass drug absorption
Class drug absorptionRaghu Prasada
 
Dental pharmacology iii
Dental pharmacology iiiDental pharmacology iii
Dental pharmacology iiiRaghu Prasada
 
Class dental pharmacology 2
Class dental pharmacology 2Class dental pharmacology 2
Class dental pharmacology 2Raghu Prasada
 
Antibiotic resistance 1
Antibiotic resistance 1Antibiotic resistance 1
Antibiotic resistance 1Raghu Prasada
 
Class thyroid and antithyroid drugs
Class thyroid and antithyroid drugsClass thyroid and antithyroid drugs
Class thyroid and antithyroid drugsRaghu Prasada
 
Class introduction to chemoTHERAPY
Class introduction to chemoTHERAPYClass introduction to chemoTHERAPY
Class introduction to chemoTHERAPYRaghu Prasada
 
Class adverse drug reaction
Class adverse drug reactionClass adverse drug reaction
Class adverse drug reactionRaghu Prasada
 
Drm science lecture MENOPAUSE AND CRYOPRESERVATION
Drm science lecture MENOPAUSE AND CRYOPRESERVATIONDrm science lecture MENOPAUSE AND CRYOPRESERVATION
Drm science lecture MENOPAUSE AND CRYOPRESERVATIONRaghu Prasada
 
Drm science lecture 2 CONTRACEPTIVES AND IUDs
Drm science lecture 2 CONTRACEPTIVES AND IUDsDrm science lecture 2 CONTRACEPTIVES AND IUDs
Drm science lecture 2 CONTRACEPTIVES AND IUDsRaghu Prasada
 
Class antileprotic drugs
Class antileprotic drugsClass antileprotic drugs
Class antileprotic drugsRaghu Prasada
 
Class oral contraceptives
Class oral contraceptivesClass oral contraceptives
Class oral contraceptivesRaghu Prasada
 
Class excretion of drugs
Class excretion of drugsClass excretion of drugs
Class excretion of drugsRaghu Prasada
 
Class sources of drugs
Class sources of drugsClass sources of drugs
Class sources of drugsRaghu Prasada
 

Mais de Raghu Prasada (20)

Class skeletal muscle relaxants
Class skeletal muscle relaxantsClass skeletal muscle relaxants
Class skeletal muscle relaxants
 
Classs drug metabolism
Classs drug metabolismClasss drug metabolism
Classs drug metabolism
 
Class antiadrenergic drugs
Class antiadrenergic drugsClass antiadrenergic drugs
Class antiadrenergic drugs
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugs
 
Class miscellaneous antibiotics
Class miscellaneous antibioticsClass miscellaneous antibiotics
Class miscellaneous antibiotics
 
Class drug absorption
Class drug absorptionClass drug absorption
Class drug absorption
 
Dental pharmacology iii
Dental pharmacology iiiDental pharmacology iii
Dental pharmacology iii
 
Class dental pharmacology 2
Class dental pharmacology 2Class dental pharmacology 2
Class dental pharmacology 2
 
Antibiotic resistance 1
Antibiotic resistance 1Antibiotic resistance 1
Antibiotic resistance 1
 
Class thyroid and antithyroid drugs
Class thyroid and antithyroid drugsClass thyroid and antithyroid drugs
Class thyroid and antithyroid drugs
 
Class introduction to chemoTHERAPY
Class introduction to chemoTHERAPYClass introduction to chemoTHERAPY
Class introduction to chemoTHERAPY
 
Class adverse drug reaction
Class adverse drug reactionClass adverse drug reaction
Class adverse drug reaction
 
Class intro to cns
Class intro to cnsClass intro to cns
Class intro to cns
 
Drm science lecture MENOPAUSE AND CRYOPRESERVATION
Drm science lecture MENOPAUSE AND CRYOPRESERVATIONDrm science lecture MENOPAUSE AND CRYOPRESERVATION
Drm science lecture MENOPAUSE AND CRYOPRESERVATION
 
Drm science lecture 2 CONTRACEPTIVES AND IUDs
Drm science lecture 2 CONTRACEPTIVES AND IUDsDrm science lecture 2 CONTRACEPTIVES AND IUDs
Drm science lecture 2 CONTRACEPTIVES AND IUDs
 
Class ccf
Class ccfClass ccf
Class ccf
 
Class antileprotic drugs
Class antileprotic drugsClass antileprotic drugs
Class antileprotic drugs
 
Class oral contraceptives
Class oral contraceptivesClass oral contraceptives
Class oral contraceptives
 
Class excretion of drugs
Class excretion of drugsClass excretion of drugs
Class excretion of drugs
 
Class sources of drugs
Class sources of drugsClass sources of drugs
Class sources of drugs
 

Último

The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Hypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxHypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxAkshay Shetty
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSapna Thakur
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 

Último (20)

The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Hypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptxHypersensitivity and its classification .pptx
Hypersensitivity and its classification .pptx
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 

Class anticholinergic drugs

  • 1. Dr. RAGHU PRASADA M S MBBS,MD ASSISTANT PROFESSOR DEPT. OF PHARMACOLOGY SSIMS & RC. 1
  • 2.  Central Nervous System (CNS) - Brain and spinal cord  Peripheral Nervous System (PNS) - Located outside the brain & spinal cord Autonomic Nervous System (ANS) & the somatic  The PNS receives stimuli from the CNS & initiates responses to the stimuli after it’s interpreted by the brain
  • 3.
  • 4.
  • 5.
  • 6.  Acetylcholine –preganglionic  Post ganglionicAch  Exception-post ganglionic sympathetic fibres to apocrine glands  Cholinergic fibres  All somatic motar neurons  All preganglionic fibres  Post ganglionic parasympathetic fibres
  • 7.  75% of all parasympathetic nerve fibers are in the vagus nerves  These nerves supply the thoracic and abdominal organs, which innervate the heart, lungs, esophagus, stomach, small intestine, proximal half of the colon, liver , gallbladder, pancreas and upper portions of the ureters
  • 8.
  • 9.
  • 10. Natural alkaloids: Atropine (spasmolytic, mydriatic), Hyoscine (Scopolamine), (antiemetic) 2. Semisynthetic derivatives Mydriatics: Homatropine, Tropicamide GI spasmolytics: Hyoscine butyl bromide 3. Synthetic compounds GI spasmolytics: Oxyphenonium Antiulcer drugs: Pirenzepine (M1-blockers) Antiasthmatics: Ipratropium and Tiotropium Urinary system: Flavoxate, Oxybutynyne, Trospium Antiparkinsonian (central M-cholinolytics): Benztropine, Biperiden, Trihexyphenidyl
  • 11.  Antimuscarinic agents: These agents block muscarinic receptors and inhibit muscarinic functions, they are useful in different clinical situations, they have no actions on skeletal neuromuscular junctions or autonomic ganglia because they do not block nicotinic receptors.
  • 12. 50 100 150 200 A B C D1 min ATROPINE BLOCKS M-EFFECTS OF ACH Bloodpressure[mmHg] ACh 2 mcg i.v. ACh 50 mcg ACh 50 mcg ACh 5 mg M- effect M- effect N- effect Atropine 2 mg i.v. ACh
  • 13. A belladonna alkaloid has a high affinity for muscarinic receptors, it is a competitive inhibitor of muscarinic receptors preventing ACH from binding to that site. Atropine
  • 14.  CNS. Atropine has an overall stimulant action. Its stimulant effects are not appreciable at low doses which produce peripheral effects because of restricted entry into the brain. Hyoscine produces central depressant effects even at low doses. • Medullar centers - vagal, respiratory, and vasоmotor. • By blocking the relative cholinergic overactivity in  basal ganglia, it suppresses tremor and rigidity  in parkinsonism. • High doses cause cortical excitation, restlessness, disorientation, hallucinations, and delirium  followed by respiratory depression and coma.
  • 15. Low dose-M2 receptor on cholinergic N auto- inhibitary cholinergic action bradycardia Moderate dose- M2 receptor on post junctional SAN, AVN blkescape the heart from inhibitiontachycardia+Unopposed adrenegic action chronotropic, dronotropic Toxic dose-M3 receptor-endothelium blockade NO release is blockedsmooth muscle donot relaxprevention of cholinergic mediated dialation
  • 16. Autonomic control of pupil (A) and site of action of mydriatics (B) and miotics (C) Topical instillation of atropine (0.1%) causes mydriasis, abolition of light reflex, and cycloplegia, lasting 7–10 days. This results in photophobia and blurring of near vision. The intraocular tension rises, specially in narrow angle glaucoma
  • 17. All visceral smooth muscles with parasympathetic innervation are relaxed (M3-blokade). Tone and amplitude of GIT are reduced. Spasm may be reduced, constipation may occur. Peristalsis is only incompletely suppressed because it is primarily regulated by local reflexes and other neurotransmitters (serotonin, encephalin, etc.).
  • 18. Atropine causes bronchodilation and reduced airway resistance, especially in asthma patients. Inflammatory mediators (histamine, PGs, and kinins) increase vagal activity in addition to their direct action on bronchial muscle and glands. Atropine attenuates their action by antagonizing the reflex vagal component. It has a relaxant action on the ureter and urinary bladder. Urinary retention can occur in older men with prostatic hyperplasia.
  • 19. Glands. Atropine decreases sweat, salivary, tracheo- bronchial, and lacrimal secretion (M3-blockade). Skin and eyes become dry, talking, and swallowing my be very difficult. Atropine decreases less the secretion of acid and pep- sin and more of the mucus in the stomach. Body temperature. Rise in body temperature occurs at higher doses, and is due to both inhibition of sweating as well as stimulation of the temperature regulating centre in the hypothalamus. Children are highly susceptible.
  • 20. Local anaesthetic action. Atropine has a mild anaesthetic action on the cornea. The sensitivity of different organs and tissues to atropine varies and can be graded as Saliva, sweat, bronchial secretion > eye > bronchial muscles > heart > intestinal and bladder smooth muscles > gastric glands and gastric smooth muscles
  • 21. Atropine and hyoscine are rapidly absorbed from GIT. Applied to the eyes they penetrate the cornea. Passage across BBB is somewhat restricted. 50% of atropine is metabolized in the liver and excreted unchanged in urine. It has t1/2 3–4 h. Hyoscine is more completely metabolized and has better BBB penetration. Some rabbits have a specific atropine esterase which degrades atropine very rapidly.
  • 22.  Scopalamine (hyoscine): A belladdona alkaloid produce peripheral effects similar to atropine, it has greater actions on CNS and longer duration of action. Most effective in motion sickness, it is effective also in blocking short term memory, it produce sedation but at higher doses cause excitement.  Depresses CNS and causes amnesia, drowsiness, euphoria, relaxation and sleep.  Given parenterally, orally and transdermally.
  • 23.  It is inhalational derivative of atropine useful in treating asthma and COPD in patients unable to take adrenergic agonist. Useful in rhinorrhea. Also excellent bronchodilator.  Agents like homatropine, cyclopentolate, and tropicamide used mainly in ophthalmology.
  • 24.  Benztropine-used in drug induced Parkinson’s disease. Useful for dystonic reactions caused by antipsychotics.  Trihexyphenidyl -also used for treating Extra Pyramidal Symptoms caused by some antipsychotics.
  • 25.  Flavoxate-relieves dysuria, urgency, frequency and pain with genito-urinary infections  Oxybutynin -has direct antispasmodic effects on smooth muscle and anticholinergic effects. Decreases frequency of voiding.  Tolterodine -is competitive, antimuscuranic anticholinergic that inhibits contraction. More selective for this area than elsewhere in the body.
  • 26. - They act on nicotinic receptors of the autonomic ganglia. - They have no selectivity toward the parasympathetic or sympathetic ganglia . - The effect of these drugs is complex and unpredictable so rarely used therapeutically, - Used mainly in experimental pharmacology. - Increase peristalsis and secretions. - On large dose of nicotine  - A)Blood pressure falls because of ganglionic blockade - B)Activity both in GIT and UB musculature decrease.
  • 27. Short acting competitive nicotinic ganglionic blocker that must be given by i.v infusion It is used for the emergency lowering of the blood pressure in hypertension caused by pulmonary edema or dissecting aortic aneurysm, when other agents cannot be used.
  • 28. - Drugs that block cholinergic transmission between motor nerve ending and the nicotinic receptors on the neuromuscular end plate of the skeletal muscle. - They are structural analogs of ACH.
  • 29.  Mydriatic and cycloplegic agent in the eye to permit measurement of refractive errors. Mydriasis and cycloplegia for surgery  RS-In bronchospasm whether related to asthma or COPD bronchodilating effects  CVS-Atropine is used to increase heart rate in symptomatic bradycardias and higher blocks  GIT-Antispasmodic agent: Relax GIT and bladder. Helpful in treating irritable colon or colitis
  • 30.  Useful in gastritis, pylorospasm and ulcerative colitis as they slow motility  Antispasmotic effects seen in overactive bladder and in urinary incontinence  Antidote for cholinergic agonists: To treat organophsphorus poisoning (present in insecticides), and mushroom poisoning. Antisecretory agent: To block the secretion of upper and lower respiratory tracts prior to surgery.  Helps to prevent vagal stimulation and potential bradycardia
  • 31. CNS- Parkinson’s Disease- Useful in those with minimal side effects Those who cannot take Levodopa Helpful in decreasing salivation, spasticity and tremors
  • 32. Absorption of other drugs is slowed because atropine delays gastric emptying. So dose of levodopa, in parkinsonism may have to be increased. But the extent of digoxin and tetracyclines absorption may be increased. Antacids interfere with the absorption of anticholinergics. Antihistaminics, tricyclic antidepressants, phenothiazines, pethidine have anticholinergic property additive side effects MAO inhibitors interfere with the metabolism of central antiparkinsonian drugs (biperiden and others) delirium may occur.
  • 33.  BPH  Myasthenia gravis  Hyperthyroidism  Glaucoma  Tachydysrhythmias
  • 34.  Dry mouth, difficulty in swallowing and talking;  Difficulty in micturition  Dilated pupils, photophobia, blurring of near vision; palpitation; excitement, psychotic behavior,  Ataxia, delirium, hallucinations; hypotension, weak and rapid pulse, cardiovascular collapse with respiratory depression;  Convulsion and coma (in very high doses).  It is very risky in individuals with glaucoma and BPH
  • 35. Diagnosis: 1 mg neostigmine s.c. fails to induce typical M-effects. Treatment: Gastric lavage with tannic acid (KMnO4 is ineffective in oxidation of atropine). The patient must be kept in a dark quiet room. Galantamine or physo- stigmine (1-3 mg s.c./i.v.), diazepam against convulsion.